作者: Norio Yasui-Furukori , Shoko Tsuchimine , Taku Nakagami , Akira Fujii , Yasushi Sato
DOI: 10.1002/HUP.1192
关键词: Brain-derived neurotrophic factor 、 Neurotrophic factors 、 Internal medicine 、 In patient 、 Beta (finance) 、 Endocrinology 、 Pathophysiology 、 Major depressive disorder 、 Antidepressant 、 Paroxetine 、 Medicine
摘要: Recent studies have implicated brain‐derived neurotrophic factor (BDNF) in the pathophysiology of depression and activities antidepressant drugs. Serum BDNF levels are lower depressed patients increase response to medications; however, no examined association between plasma concentrations drugs levels. We assessed paroxetine 45 with major who were being treated paroxetine. Plasma samples collected 10:00 h 12:00 at baseline after 1, 2 6 weeks treatment. The level concentration each sample measured via enzyme immunoassay high‐performance liquid chromatography, respectively. increased significantly men than women. Changes correlated drug (r = 0.309, p < 0.05) 0.329, but not 1 week 0.284, ns). Multiple regression analysis confirmed that this change was only (standardised beta 0.343, 0.375, 0.05). These results suggest treatment increases play an important role changes